Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68084-776

11 FDA label images from American Health Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68084-776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp77601

Ahp77601
Divalproex Sodium 250 mg or 500 mg extended-release tablets, capsule-shaped and scored, reddish-orange in color. One side is imprinted with the code 'D 85'. Labeler is American Health Packaging. Appropriate for prescription use.*
FDA Label Image

Ahp78261

Ahp78261
Image of two oblong, purplish-pink tablets, one imprinted with "D 86" and the other plain. These tablets correspond to Divalproex Sodium, available in 250 mg and 500 mg strengths, as labeled by American Health Packaging.*
FDA Label Image

Chemical Structure (Structure)

Chemical Structure (Structure)
Chemical structure of divalproex sodium depicted as a repeating polymer unit containing sodium salt and carboxylate groups linked to branched alkyl chains.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
Bar graph comparing percentage outcomes between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) in two studies labeled YMRS and MRS. The graph shows higher percentages for divalproex sodium groups (60% and 58%) compared to placebo groups (26% and 29%). An asterisk indicates statistical significance (p < 0.05).*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A line graph showing the percentage reduction in CPS rate versus percentage of patients for Divalproex Sodium Delayed-Release Tablets compared to placebo. The graph illustrates treatment effect, with the y-axis representing % reduction in CPS rate and the x-axis representing % of patients. Positive values indicate improvement, negative values indicate worsening.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A graph titled Figure 3 showing the percentage reduction in CRS rate on the vertical axis against the percentage of patients on the horizontal axis. Two lines represent treatment groups: a solid line for high dose and a dashed line for low dose. The vertical axis is annotated with 'Improvement' upwards and 'Worsening' downwards, with a 'No Change' marker at zero percent reduction.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
Bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates over four weeks between placebo and Divalproex Sodium delayed-release tablets in two studies. The vertical axis ranges from 0 to 6 migraine rates. Study 1 and Study 2 data show lower migraine rates for Divalproex Sodium delayed-release tablets compared to placebo.*
FDA Label Image

250 mg_divalproex_sodium_dr_tablets_carton.jpg (250 mg Divalproex Sodium Dr Tablets Carton)

250 mg_divalproex_sodium_dr_tablets_carton.jpg (250 mg Divalproex Sodium Dr Tablets Carton)
Label for Divalproex Sodium Delayed-Release Tablets USP, 250 mg strength, containing 100 tablets (10 x 10) from American Health Packaging. The label includes NDC 68084-776-01, specifies valproic acid activity, and notes the product is prescription only with pharmacist instructions to dispense with a medication guide.*
FDA Label Image

250-mg-divalproex-sodium-dr-tablet-blister.jpg (250 mg Divalproex Sodium Dr Tablet Blister)

250-mg-divalproex-sodium-dr-tablet-blister.jpg (250 mg Divalproex Sodium Dr Tablet Blister)
Label sheet containing multiple instances of Divalproex Sodium 250 mg delayed-release tablet labels. Each label displays the product name, strength, dosage form, barcodes, lot number, expiration date, and the labeler American Health Packaging, Columbus, Ohio.*
FDA Label Image

500 mg_divalproex_sodium_dr_tablets_carton.jpg (500 mg Divalproex Sodium Dr Tablets Carton)

500 mg_divalproex_sodium_dr_tablets_carton.jpg (500 mg Divalproex Sodium Dr Tablets Carton)
Divalproex Sodium delayed-release tablets 500 mg, 90 count (9 x 10 tablets) label. The label includes the National Drug Code (NDC) 68084-782-61, highlights valproic acid activity, and specifies 'Rx Only.' Manufacturer information states distribution by American Health Packaging, Columbus, Ohio. Additional text covers storage instructions and pharmacist dispensing guidance.*
FDA Label Image

500-mg-divalproex-sodium-dr-tablet-blister.jpg (500 mg Divalproex Sodium Dr Tablet Blister)

500-mg-divalproex-sodium-dr-tablet-blister.jpg (500 mg Divalproex Sodium Dr Tablet Blister)
Label for Divalproex Sodium 500 mg delayed-release tablets by American Health Packaging. The label includes dosage strength, tablet form, lot number 1234567, and expiration date 10/22. The label is repeated for multiple tablets and includes barcodes and manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.